Skip to main content
News Icon

News categories: Publication

How tumor cells evade the immune system

A new study by the University of Bonn and research institutions in Australia and Switzerland shows the strategies that tumor cells use to avoid being attacked by the imune system.
The method developed for this work contributes to a better understanding of the "arms race" between immune defense and disease. The results could help to improve modern therapeutic approaches and were published in 'Immunity'.

Cancer cells differ from healthy body cells - by their appearance, by their behavior, by the genes that are active in them. Often this does not go unnoticed: the immune system registers that something is wrong and sends its troops to fight the tumor. However, this answer is often too weak to keep cancer at bay in the long term or even to destroy it. Scientists have therefore been trying to strengthen the immune system's response for many years.

Many tumors have developed strategies that can help them escape the immune system. "In our study, we examined what these strategies look like and what they depend on," explains Dr. Maike Effern from the Institute of Experimental Oncology at the University Hospital Bonn. "We focused on melanoma cells, i.e. black skin cancer."

"When T cells were directed against genes that are responsible for melanoma-typical traits, we observed that the cancer cells changed their appearance and suppressed these genes over time," explains Effern's colleague Dr. Nicole Glodde. "So they hid from the immune system."

"Our work may open the way to more effective immunotherapy," hopes Prof. Dr. Michael Hölzel, head of the Institute of Experimental Oncology at the University Hospital Bonn and member of the Cluster of Excellence ImmunoSensation at the University of Bonn. "The method we developed also allows us to better understand the processes by which cancer cells slip under the radar of the immune system."


Publication

Maike Effern, Nicole Glodde, Matthias Braun, Jana Liebing, Helena N. Boll, Michelle Yong, Emma Bawden, Daniel Hinze, Debby van den Boorn-Konijnenberg, Mila Daoud, Pia Aymans, Jennifer Landsberg, Mark J. Smyth, Lukas Flatz, Thomas Tüting, Tobias Bald, Thomas Gebhardt, Michael Hölzel: Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma. Immunity

Contact

Prof. Dr. Michael Hölzel

Institute of Experimental Oncology, Unversity

Hospital Bonn

Phone: 0228/287-12170

E-Mail: michael.hoelzel@ukbonn.de

Related news

Kathrin Leppek Publication PM

News categories: Publication

Starting points for the control of protein synthesis

The research field of "cellular IRESes" lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated control of gene expression. Researchers at the University Hospital Bonn (UKB) and the University of Bonn, in collaboration with Stanford University in California (USA), have now developed a toolbox as a new gold standard for this field. The results of their work have been published in The EMBO Journal.
View entry
Pandyra Publication Graphical Abstract

News categories: Publication

Genetic mutation affects survival after viral infection

Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

News categories: Publication

Potential target for MS therapy discovered

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview